Mobidiag Receives €10M Equity Investment

mobidiagMobidiag Ltd., an Espoo, Finland-based commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, completed a €10m equity investment.

Autobio Diagnostics made the investment.

The company intends to use the funds to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system and enhance its manufacturing capabilities, as well as continuing to facilitate commercial expansion.

Led by Tuomas Tenkanen, CEO, Mobidiag provides a molecular diagnostics solution allowing fully automated detection of infectious diseases, including antibiotic resistances. The platform combines real-time PCR and microarray technologies, to allow direct analysis of samples placed in a disposable cartridge. It also allows for comprehensive screening of multiple or single pathogens within approximately one hour, allowing clinicians to be informed when making time-critical decisions, in order to deliver early treatments and avoid the spread of infection.
The company is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden.



Join the discussion